Loading
A phase 2 trial of Psilocybin therapy in endometrial cancer, prostate cancer, gastric & gastro-oesophageal junction cancer, melanoma and pancreatic ductal adenocarcinoma, run by Psyence Australia Pty Ltd, now recruiting.
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder is a phase 2 interventional study registered as NCT07072728 by Psyence Australia Pty Ltd, with 87 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Psilocybin therapy.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Melanoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Prostate cancer and the tag pipeline.
Shares Melanoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.